https://www.selleckchem.com/pr....oducts/ly2584702.htm
Immune checkpoint inhibitors (ICIs) have shown remarkable success in treating skin cutaneous melanoma (SKCM); however, the response to treatment varies greatly between patients. Considering that the efficacy of ICI treatment is influenced by many factors, we selected the Fibrosheath interacting protein 2 (FSIP2) gene and systematically analyzed its potential to predict the efficacy of ICI treatment. Patient data were collected from an ICI treatment cohort ( = 12 and a The Cancer Genome Atlas (TCGA)-SKCM cohort ( = 467). The data wer
Aimer
Commentaire
Partagez
